Respiratory Tract Infection Treatment Market, by Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, and Others), by Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, trends, and Forecast to 2026

  • Published On : Aug 2018 |
  • Pages : 157 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Respiratory Tract Infection Treatment Market – Insights

Respiratory diseases such as bronchitis, asthma, allergic rhinitis, pneumonia, and sinusitis can significantly curtail the physical activities of the individual. The symptoms associated with both mild and severe indication of these respiratory conditions include coughing, wheezing, chest pain, respiratory distress, and shortness of breath, congestion, and even death in severe cases. These conditions lead to substantial morbidity and causes large cost of burden to the society.

Therefore, the development of new drugs with less adverse effects for the treatment of respiratory tract infection is a major concern for manufacturers, as there are many generic players in the market, occupying majority of the market share.

The global respiratory tract infection treatment market was valued at US$ 35.64 Bn in 2017, and is expected to witness a CAGR of 6.5% over the forecast period (2018 – 2026).

                   Figure 1. Global Respiratory Tract Infection Treatment Market Share Analysis (%), By Product Type                                        Respiratory Tract Infection Treatment  | Coherent Market Insights  

Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of respiratory diseases is expected to drive growth of the respiratory tract infection treatment market

Increasing prevalence of chronic respiratory diseases such as asthma, chronic pulmonary lung disease, pulmonary hypertension, and occupational lung disease are the major factors augmenting growth of the respiratory tract infection market.

For instance, according to the Biomed Central Respiratory Research 2016, asthma and chronic obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders characterized by variable airflow limitation and airway hyper responsiveness, affecting over 25 million people in the U.S.

Various organizations, institutions, and agencies are working towards improving the diagnosis and medical care needed to reduce the global burden of respiratory diseases. For instance, the Global Alliance against Chronic Respiratory Diseases (GARD) was formed with the support from the World Health Organization (WHO) to control chronic respiratory diseases. The main objective of GARD is to develop simple and affordable strategies for chronic respiratory diseases (CRD) and to encourage economies to implement health promotion and CRD prevention policies.

Presence of various drugs in pipeline, which is expected to be launched over the forecast period will also boost the market growth of respiratory tract infection treatment. Some of the drugs in the pipeline include Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead), AZD7594, and PT010 (AstraZeneca).

However, presence of various generic manufacturers and low cost of various drugs including antibiotics in the market may hinder the respiratory tract infection treatment market to some extent during the forecast period.

Respiratory Tract Infection Treatment Market- Regional Analysis

On the basis of region, the global respiratory tract infection treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the global respiratory tract infection treatment market over the forecast period, owing to increasing number of hospitalizations and emergency visits associated with acute or life threatening medical problems.

According to the study by Society of Critical Care Medicine 2016, over 5.7 million patients are admitted annually in intensive care units (ICUs) in the U.S. for support of airway, breathing or circulation, and comprehensive management of injury.

Also, according to the Centers for Disease Control and Prevention (CDC), 2017, around 1.7 million emergency department visits with chronic and unspecified bronchitis were registered in the U.S. hospital facilities.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding their business in Asia Pacific region, to maximize their R&D activities, as this region provides better access to patients for clinical trials, with low cost operational efficiencies. Increasing government investments in research and development, patient awareness, improved health care infrastructure and facilities, high disposable income, and prevalence of unhealthy lifestyle are also expected to foster growth of the respiratory tract infection treatment market in the Asia Pacific region.

Figure 2: Global Respiratory Tract Infection Treatment Market Share (%), By Region

Respiratory Tract Infection Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Respiratory Tract Infection Treatment Market- Competitive Landscape

Increasing approval of new drugs by the Food and Drug Administration (FDA) is also expected to propel the overall market growth over the forecast period. For instance, in November 2017, the U.S. FDA approved Fasenra (Benralizumab) manufactured by AstraZeneca, a respiratory biologic for patients aged 12 years and older who are suffering from asthma, and with an eosinophilic phenotype.

Key players operating in the global respiratory tract infection treatment market include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.

Respiratory tract infection is any infection in the nose, sinuses around the nose, throat (pharynx), voice box (larynx), and windpipe (trachea), airways (bronchi) or lungs, which may occur anytime, usually beginning with cold. This infection is usually caused by bacteria and viruses. Virus prone respiratory tract infection are easily transmitted and very contagious while bacterial infection can also be developed during the course of an upper respiratory tract infection. Respiratory tract infection is generally divided into two categories- upper respiratory tract infection (infection in nose, throat, and pharynx) and lower respiratory tract infection (infection below the larynx).

Market Dynamics

The global respiratory tract infection market is expected to witness lucrative growth due to factors such as increasing prevalence of lung diseases, surge in geriatric population, and rising risk of pneumonia in children. According to the World Health Organization (WHO), respiratory syncytial virus (RSV) is responsible for around 30 million lower respiratory tract infection cases in children worldwide. The prevalence of such viral diseases is expected to drive growth of the global market over the forecast period. 

Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies have shown effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies.

However, adverse effects of using NSAIDs and antibiotics on patients suffering from respiratory tract infection may hinder growth of the market. In 2015, the U.S. Food and Drug Administration (FDA) increased the warning labels on over-the-counter NSAIDs to highlight elevated risks for heart attack and stroke.

Key features of the study:

  • This report provides in-depth analysis of the respiratory tract infection treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global respiratory tract infection treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global respiratory tract infection treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for respiratory tract infection treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Respiratory Tract Infection Treatment Market, By Drug Class:
    • Antibiotics
    • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
    • Cough Suppressant
    • Nasal Decongestant
    • Others
  • Global Respiratory Tract Infection Treatment Market, By Disease Indication:
    • Upper Respiratory Tract Infection
    • Lower Respiratory Tract Infection
  • Global Respiratory Tract Infection Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Respiratory Tract Infection Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Antibiotics
        • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
        • Cough Suppressant
        • Nasal Decongestant
        • Others
      • By Disease Indication:
        • Upper Respiratory Tract Infection
        • Lower Respiratory Tract Infection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Antibiotics
        • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
        • Cough Suppressant
        • Nasal Decongestant
        • Others
      • By Disease Indication:
        • Upper Respiratory Tract Infection
        • Lower Respiratory Tract Infection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Antibiotics
        • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
        • Cough Suppressant
        • Nasal Decongestant
        • Others
      • By Disease Indication:
        • Upper Respiratory Tract Infection
        • Lower Respiratory Tract Infection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Antibiotics
        • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
        • Cough Suppressant
        • Nasal Decongestant
        • Others
      • By Disease Indication:
        • Upper Respiratory Tract Infection
        • Lower Respiratory Tract Infection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Antibiotics
        • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
        • Cough Suppressant
        • Nasal Decongestant
        • Others
      • By Disease Indication:
        • Upper Respiratory Tract Infection
        • Lower Respiratory Tract Infection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Antibiotics
        • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
        • Cough Suppressant
        • Nasal Decongestant
        • Others
      • By Disease Indication:
        • Upper Respiratory Tract Infection
        • Lower Respiratory Tract Infection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Abbott Laboratories*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • AstraZeneca, Plc
    • Abbvie Inc.
    • Boehringer Ingelheim GmbH
    • Cipla Pharmaceutical Company
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Merck & Co.
    • Novartis AG
    • F. Hoffman La Roche Ltd
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Pipeline Analysis
    • Epidemiology
    • PEST Analysis
    • PORTER’S Analysis
  4. Global Respiratory Tract Infection Treatment Market, By Drug Class, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
    • Non-Steroidal Anti-Inflammatory Drug (NSAIDS)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
    • Cough Suppressant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
    • Nasal Decongestant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
  5. Global Respiratory Tract Infection Treatment Market, By Disease Indication, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Upper Respiratory Tract Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
    • Lower Respiratory Tract Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
  6. Global Respiratory Tract Infection Treatment Market, By Distribution Channel, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
  7. Global Respiratory Tract Infection Treatment Market, By Region, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2016–2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016–2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016–2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016–2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016–2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016–2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016–2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca, Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abbvie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Cipla Pharmaceutical Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
      • F. Hoffman La Roche Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 25 market data tables and 22 figures on "Respiratory Tract Infection Treatment Market” - Global forecast to 2026”

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.